Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acne
Biotech
Dermata's midstage rosacea study sees far-from-rosy results
Dermata's lead asset failed a phase 2 study in rosacea, due in part to high dropout and placebo response rates.
Max Bayer
Dec 5, 2022 11:11am
New study says the source of acne may be broken macrophages
Jul 26, 2022 6:00am
AnaptysBio's ACORN fails, marking end of acne program
Mar 15, 2022 7:45am
Skin fibroblasts play role in acne formation
Feb 22, 2022 8:40am
Discovery of genetic variants could aid new acne treatments
Feb 7, 2022 11:51am
Sanofi snaps up Origimm for acne vaccine, plans mRNA prospect
Dec 1, 2021 2:14am
